These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11261648)

  • 1. Compliance with antipsychotic treatment.
    Oehl M; Hummer M; Fleischhacker WW
    Acta Psychiatr Scand Suppl; 2000; (407):83-6. PubMed ID: 11261648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial compliance in schizophrenia and the impact on patient outcomes.
    Llorca PM
    Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Compliance problems in treatment of schizophrenic patients].
    Barnas C; Hummer M; Fleischhacker WW
    Wien Med Wochenschr; 1998; 148(11-12):281-3. PubMed ID: 9746971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial compliance and patient consequences in schizophrenia: our patients can do better.
    Keith SJ; Kane JM
    J Clin Psychiatry; 2003 Nov; 64(11):1308-15. PubMed ID: 14658944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
    Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
    J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The meaning of antipsychotic medication to patients with schizophrenia.
    Seeman MV; Seeman N
    J Psychiatr Pract; 2012 Sep; 18(5):338-48. PubMed ID: 22995961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
    Misdrahi D; Llorca PM; Lançon C; Bayle FJ
    Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [To increase compliance-knowledge. Only every second schizophrenia patient remains faithful to the therapy].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579500
    [No Abstract]   [Full Text] [Related]  

  • 14. The natural course of schizophrenia and effective maintenance drug treatment.
    Davis JM; Andriukaitis S
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):2S-10S. PubMed ID: 2870087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
    Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
    Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of medication compliance in schizophrenia: empirical and clinical findings.
    Fenton WS; Blyler CR; Heinssen RK
    Schizophr Bull; 1997; 23(4):637-51. PubMed ID: 9366000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [If drugs are not taken - how different antipsychotics influence compliance of schizophrenic patients].
    Schorr SG; Brouwers JR; Taxis K
    Fortschr Neurol Psychiatr; 2007 Aug; 75(8):473-7. PubMed ID: 17638181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of interventions to improve compliance with antipsychotic medication in people suffering from schizophrenia-results of recent reviews].
    Puschner B; Born A; Giessler A; Helm H; Becker T; Angermeyer MC
    Psychiatr Prax; 2005 Mar; 32(2):62-7. PubMed ID: 15712037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.